课题基金 / 基金详情

PHASE I STUDY OF DOCETAXEL AND DOXORUBICIN COMBINATION CHEMOTHERAPY

PHASE I STUDY OF DOCETAXEL AND DOXORUBICIN COMBINATION CHEMOTHERAPY
多西紫杉醇和阿霉素联合化疗的 I 期研究
批准号：
6281037
负责人：
ERIC K ROWINSKY
金额：
$1.49万
依托单位：
UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
项目状态：
已结题
起止时间：
1997-12-01 至 1998-11-30
来源：
https://reporter.nih.gov/project-details/6281037
关键词：
antineoplastics clinical research clinical trial phase I combination chemotherapy dosage doxorubicin drug interactions human subject human therapy evaluation neoplasm /cancer chemotherapy paclitaxel

项目摘要

项目成果

ERIC K ROWINSKY的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The purpose of this study is to determine the maximum tolerated dose of docetaxel and doxorubicin in combination when given to patients with solid tumors. As single chemotherapeutic agents, both drugs have shown a broad spectrum of activity in solid tumors; it is hoped that, in combination, the agents will exert a synergistic effect. The study has been extended to January, 1999.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Ph I Study Of BMS-247550 In PTS with advanced Neoplasms
Phase II Pharmacologic/Biologic Study of Thalidomide
Ph I Pharmacokinetics of NSC-655649/Cisplatin/G-CSF
PHASE I TRIAL OF LY231514 IN PATIENTS W/ VARYING DEGREES OF RENAL FUNCTION
海外基金